Cyclotherapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Alachua FL United States (1990)

Organization Overview

First Clinical Trial
2017
NCT02912793
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CTD Holdings, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

Key: Cyclotherapeutics (1) Acquired (2)

adalimumab (humira) (1 trial)

amt-101 (4 trials)

hydroxypropyl-beta-cyclodextrin (3 trials)

Drugs in Phase 1 Trials (1)

Key: Cyclotherapeutics (0) Acquired (1)

amt-126 (1 trial)

Drugs in Other Trials (1)

cyclodextrin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aphasia, Primary Progressive (Phase 2)

Frontotemporal Dementia (Phase 2)

Niemann-Pick Diseases (Phase 2)

Niemann-Pick Disease, Type A (Phase 2)

Niemann-Pick Disease, Type C (Phase 2)

Pick Disease of the Brain (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 5